anchor Taniguchi H, Nakamura Y, Kotani D, et al. "CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer." Cancer Sci. 2021;112(7):2915-2920. The umbrella protocol/design paper for the CIRCULATE-Japan platform that the sub-topic's spine names directly. It defines the three linked arms built off a shared ctDNA-screening registry: GALAXY (prospective observation, anchored at nod_6055e3f3), VEGA (randomized de-escalation — postoperative surgery-alone vs CAPOX in ctDNA-negative high-risk stage II / low-risk stage III colon cancer), and ALTAIR (randomized escalation — trifluridine/tipiracil vs placebo in ctDNA/MRD-positive resected CRC). It establishes the adaptive-platform logic by which post-resection ctDNA status routes patients toward de-escalation (if negative) or escalation (if positive) — the structural backbone of the sub-topic's question. Design caveat: the platform spans stage II-IV CRC and this node is the protocol, not a readout; its bearing on the sub-topic's resected stage II colon question is structural (it frames how the GALAXY/VEGA/ALTAIR evidence is generated), with the individual arm readouts being the natural propose_anchor/propose_supersedes follow-ups as they publish.

nod_a629b95c-23fd-4931-8a6b-df94b5b7c19a

Source

No active edges touch this node yet — an isolated point in the graph (or, for a freshly accepted anchor, awaiting an excerpt).